hyperCORE International has announced that Empathx Clinical Research, a Tampa Bay-based clinical research organization operating eight sites across six states, has joined its global partner site network. This partnership aims to expand patient access to clinical trials and strengthen the network's capabilities in the United States.
Empathx Clinical Research focuses on advancing clinical trials in cardio-metabolic disease, central nervous system (CNS) disorders, nephrology, and infectious disease. Its eight sites are located in California, Florida, Massachusetts, Michigan, Missouri, and Texas. The organization employs a hybrid model that includes both dedicated stand-alone research centers and integrated research sites embedded within large specialized physician practices. This approach brings clinical research directly into care environments where patients already receive treatment, expanding access to trials while supporting efficient study execution.
CEO Dustin Owen, who previously served as Senior Vice President of Accelerated Enrollment Solutions at Thermo Fisher Scientific/PPD, emphasized the strategic alignment: "Joining hyperCORE is about partnering with like-minded, high quality site networks with similar mission. The partnership enhances our ability to work with sponsors to bring life-changing therapies to our communities. Our added scale, geographic coverage, and access to diverse patient populations gives sponsors a reliable solution for delivering on clinical trials."
Nicholas Focil, President of hyperCORE International, welcomed Empathx, stating, "Empathx Clinical Research brings a strong blend of therapeutic expertise, geographic reach, and innovative site integration to our partner network. Their approach to embedding research in clinical care aligns with hyperCORE's mission to expand patient access and deliver high-quality trials, and we are pleased to welcome Empathx to the network."
hyperCORE International is a partner site network comprising leading clinical research organizations, with more than 80 active trial sites across five countries. Collectively, hyperCORE partners have completed over 7,000 studies involving more than 140,000 randomized participants. The network aligns independent organizations around harmonized operational frameworks that support high-quality, consistent trial execution. hyperCORE is committed to advancing clinical research through safe, ethical studies, strong enrollment, and superior patient retention.
The addition of Empathx Clinical Research strengthens hyperCORE's ability to provide sponsors with diverse patient populations and integrated research sites, particularly in the southern and western United States. This expansion is significant as the clinical research industry increasingly seeks to improve patient access and accelerate trial timelines through innovative site models. By joining hyperCORE, Empathx gains access to a network that supports operational harmonization and collaborative opportunities, potentially enhancing its ability to attract and execute complex trials.
